Mayne Pharma Group (MYX) Scheme meeting 2026 summary
Event summary combining transcript, slides, and related documents.
Scheme meeting 2026 summary
17 Nov, 2026Opening remarks and agenda
Gedeon Richter or its Australian subsidiary proposed acquiring all shares for A$6.40 cash per share, valuing equity at ~A$604m and representing a 99.4% premium to the 16 Nov 2026 closing price.
Financial performance review
Richter reported FY2025 sales of EUR 2.3bn and an EBIT margin of 31.5%; women’s healthcare sales were EUR 826m, with contraception and menopause contributing 68%.
Richter described itself as Europe’s second-largest women’s healthcare company.
Board and executive committee updates
Board unanimously recommends voting for the Scheme, absent a Superior Proposal and subject to the Independent Expert continuing to consider it in shareholders’ best interests.
Directors intend to vote shares they hold or control in favour, subject to the recommendation conditions; the CEO said business-as-usual operations and priorities continue until implementation.
The three largest shareholders, holding 22.14% of shares on issue together, intend to vote in favour, absent a Superior Proposal.
Latest events from Mayne Pharma Group
- MPI sale for AUD 55.5m lifts pro forma cash to AUD 122.8m and sharpens U.S. focus.MYX
Investor update - Women's Health and DistributeRx growth offset by Dermatology erosion and lower EBITDA.MYX
Q1 2027 TU - Branded mix rose to 83%, lifting FY26 gross margin to 64.7%.MYX
Investor presentation - Revenue down 6% to $383.7M, net profit $31.2M, gross margin up to 64.7%.MYX
H2 2026 - Gross margin rose to 65.3% as Dermatology drove contribution growth and net loss narrowed.MYX
H1 2026 - Underlying EBITDA up 105% to $47.0m, revenue $408.1m, Cosette deal advances.MYX
H2 2025 - Shareholders overwhelmingly approved a proposed A$7.40-per-share scheme, pending court and regulatory clearance.MYX
AGM 2025 - Revenue up 112% and underlying EBITDA positive, led by Women's Health and Dermatology growth.MYX
H2 2024 - Revenue up 13%, EBITDA up 288%, and Cosette acquisition at a 57% premium announced.MYX
H1 2025